A. A pharma company s desire to balance control over drug development with fluctuations in workload. B. The pharma company trying to reduce its fixed investment in development by buying CROs. C. The desire to reduce competition with smaller biotech companies. D. A desire for the pharma companies to build their in-house development capability.